<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074500</url>
  </required_header>
  <id_info>
    <org_study_id>09.2017.004</org_study_id>
    <nct_id>NCT03074500</nct_id>
  </id_info>
  <brief_title>Kinesiotaping in Lateral Epicondylitis</brief_title>
  <official_title>A Randomized Controlled Trial Comparing the Effects of Kinesiology Taping With Exercise, Sham Taping With Exercise and Exercise Alone for Lateral Epicondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marmara University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effects of kinesiology taping with exercise, sham
      taping with exercise and exercise alone for lateral epicondylitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lateral epicondylitis or tennis elbow is a often-encountered disorder of elbow which is
      characterized by tenderness and pain over lateral epicondylitis of humerus and grip weakness.
      The annual incidence of lateral epicondylitis has been reported to be %1-3 in general
      population. Lateral epicondylitis is commonly associated with repetitive overuse of wrist,
      activities including strong grip which in turn cause microtears and degenerative changes over
      the common origin of wrist and finger extensors on lateral epicondyle. New researches have
      shown that the underlying mechanism is degenerative rather than inflammatory. It has been
      proposed that the cause of pain may be mechanical discontinuity of collagen fibers or
      biochemical irritation that results from damaged tendon tissue that activates nociceptors. It
      has been suggested that eccentric loading has been shown to assist with tendon rehabilitation
      by improving collagen alignment and stimulating collagen cross-linkage formation, both of
      which can improve tensile strength.

      Kinesio taping (KT) which is a new application of adhesive taping was designed by Kenzo Kase
      to avoid unwanted effects of conventional taping such as restricting range of motion (ROM)
      and limiting functional activities. The recommended tape application methods are outlined in
      'Clinical Therapeutic Applications of the Kinesio Taping Method' 8. Elastic therapeutic tape
      has been designed to allow for a longitudinal stretch of up to 140% of its resting length and
      has been designed to approximate the elastic qualities of the human skin. In particular, the
      application of the tape over stretched muscle to create convolutions in the skin has been
      hypothesized to reduce pressure in the mechanoreceptors below the dermis, thereby decreasing
      nociceptive stimuli. Another mechanism which is claimed by the proponent of the tape is that
      convolutions are raised ridges of the tape and the skin that are thought to decompress
      underlying structures and allow for enhanced circulation by increased subcutaneous space. In
      the last few years, the use of KT has become increasingly popular in rehabilitation programs
      as an adjunct in the treatment. However, scientific evidence about its effect is
      insufficient.

      The aim of this study is to compare the effects of kinesiology taping with exercise, sham
      taping with exercise and exercise alone for lateral epicondylitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>To ensure group concealment, randomization will be done by using opaque, sealed envelopes which the assessors will be blinded to</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Rated Tennis Elbow Evaluation (PRTEE)</measure>
    <time_frame>0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)</time_frame>
    <description>PRTEE is a 15-item questionnaire designed to measure the forearm pain and disability in patients with LE. PRTEE allows patients to rate their levels of elbow pain and disability from 0 to 10. Test consists of 2 subscales: 1) Pain subscale [5 items] (0 = no pain, 10 = worst imaginable) 2) Function subscale [Specific activities - 6 items, Usual activities - 4 items] (0 = no difficulty, 10 = unable to do). A total score can be computed on a scale of 100 (0 = no disability).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Disabilities of the Arm, Shoulder and Hand Score (QuickDash)</measure>
    <time_frame>0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)</time_frame>
    <description>The patients will be requested to score from 1 to 5 points any difficulty experienced during different daily activities related to the upper extremity. Test has 1 module of compulsory items and two optional modules: work module (4 items) and sport/performing arts module (4 items). Scores range from 0 to 100, where higher scores indicate more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) at Rest</measure>
    <time_frame>0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)</time_frame>
    <description>Pain on lateral epicondyle at rest during the day was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) at Daily Activity</measure>
    <time_frame>0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)</time_frame>
    <description>Pain on lateral epicondyle during daily activity was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) at Night</measure>
    <time_frame>0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)</time_frame>
    <description>Pain on lateral epicondyle at night was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painless Grip Strength</measure>
    <time_frame>0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)</time_frame>
    <description>Grip strength will be measured using a hand held dynamometer (JAMAR, Sammons Preston, Inc., Bolingbrook, IL). Patients will be asked to grip the dynamometer until (s)he feel pain in elbow. Three evaluations will be made with resting periods in between and average scores will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)</time_frame>
    <description>Grip strength will be measured using a hand held dynamometer (JAMAR, Sammons Preston, Inc., Bolingbrook, IL). Patients will be asked to grip with maximum strength. Three evaluations will be made with resting periods in between and average scores will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Lateral Epicondylitis</condition>
  <arm_group>
    <arm_group_label>Kinesiotaping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham taping</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stretching and strengthening exercises of wrist</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Kinesiotaping</intervention_name>
    <description>Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis</description>
    <arm_group_label>Kinesiotaping</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham taping</intervention_name>
    <description>Sham taping will be performed without using any technique</description>
    <arm_group_label>Sham taping</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Kinesiotaping</arm_group_label>
    <arm_group_label>Sham taping</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Having had symptoms less than 12 weeks

          2. Tenderness and pain over lateral epicondylitis

          3. Provocation of the lateral elbow pain with at least one of the following tests -
             resisted middle finger extension (Maudley's test), resisted wrist extension or passive
             stretch of wrist extensors (Mill's test).

        Exclusion Criteria:

          1. Cervical spondylosis or radiculopathy

          2. Diabetes mellitus

          3. Neuropathy

          4. Arthritis in the upper extremities

          5. History of injection and physical therapy for lateral epicondylitis within the last
             three months

          6. Pregnancy

          7. History of surgery or acute trauma in the elbow

          8. Allergy to tape
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gulseren Derya Akyuz, MD,Prof</last_name>
    <role>Study Director</role>
    <affiliation>Marmara University School of Medicine, PM&amp;R Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esra Giray</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marmara University School of Medicine, PM&amp;R Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marmara University School of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Wegener RL, Brown T, O'Brien L. A randomized controlled trial of comparative effectiveness of elastic therapeutic tape, sham tape or eccentric exercises alone for lateral elbow tendinosis. Hand Therapy 2016;21(4):131-9.</citation>
  </reference>
  <reference>
    <citation>Kase K. Clinical therapeutic applications of the Kinesio taping methods. 2016.</citation>
  </reference>
  <results_reference>
    <citation>Lee SS, Kang S, Park NK, Lee CW, Song HS, Sohn MK, Cho KH, Kim JH. Effectiveness of initial extracorporeal shock wave therapy on the newly diagnosed lateral or medial epicondylitis. Ann Rehabil Med. 2012 Oct;36(5):681-7. doi: 10.5535/arm.2012.36.5.681. Epub 2012 Oct 31.</citation>
    <PMID>23185733</PMID>
  </results_reference>
  <results_reference>
    <citation>Küçükşen S, Yilmaz H, Sallı A, Uğurlu H. Muscle energy technique versus corticosteroid injection for management of chronic lateral epicondylitis: randomized controlled trial with 1-year follow-up. Arch Phys Med Rehabil. 2013 Nov;94(11):2068-74. doi: 10.1016/j.apmr.2013.05.022. Epub 2013 Jun 22.</citation>
    <PMID>23796685</PMID>
  </results_reference>
  <results_reference>
    <citation>Struijs PA, Smidt N, Arola H, Dijk vC, Buchbinder R, Assendelft WJ. Orthotic devices for the treatment of tennis elbow. Cochrane Database Syst Rev. 2002;(1):CD001821. Review.</citation>
    <PMID>11869609</PMID>
  </results_reference>
  <results_reference>
    <citation>Guo YH, Kuan TS, Chen KL, Lien WC, Hsieh PC, Hsieh IC, Chiu SH, Lin YC. Comparison Between Steroid and 2 Different Sites of Botulinum Toxin Injection in the Treatment of Lateral Epicondylalgia: A Randomized, Double-Blind, Active Drug-Controlled Pilot Study. Arch Phys Med Rehabil. 2017 Jan;98(1):36-42. doi: 10.1016/j.apmr.2016.08.475. Epub 2016 Sep 22.</citation>
    <PMID>27666156</PMID>
  </results_reference>
  <results_reference>
    <citation>Altan L, Kanat E. Conservative treatment of lateral epicondylitis: comparison of two different orthotic devices. Clin Rheumatol. 2008 Aug;27(8):1015-9. doi: 10.1007/s10067-008-0862-8. Epub 2008 Mar 26.</citation>
    <PMID>18365136</PMID>
  </results_reference>
  <results_reference>
    <citation>Dilek B, Batmaz I, Sarıyıldız MA, Sahin E, Ilter L, Gulbahar S, Cevik R, Nas K. Kinesio taping in patients with lateral epicondylitis. J Back Musculoskelet Rehabil. 2016 Nov 21;29(4):853-858.</citation>
    <PMID>27232082</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <results_first_submitted>May 2, 2018</results_first_submitted>
  <results_first_submitted_qc>October 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2019</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kinesio taping</keyword>
  <keyword>lateral epicondylitis</keyword>
  <keyword>tennis elbow</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tennis Elbow</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03074500/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03074500/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period was March 2017-May 2017 Setting: A university hospital outpatient clinics</recruitment_details>
      <pre_assignment_details>Number of patients assessed for eligibility was 41. Among them,8 participants were excluded due to being inappropiate for the inclusion criteria (2 had concomittant radiculopathy, 2 were diagnosed as cubital tunnel syndrome, 2 were diagnosed as carpal tunnel syndrome and 2 of them had duration of symptoms were more than 12 weeks)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Kinesiotaping</title>
          <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
        </group>
        <group group_id="P3">
          <title>Sham Taping</title>
          <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kinesiotaping</title>
          <description>Kinesio taping by using space and fascia correction techniques on forearm of the patients for lateral epicondylitis treatment will be applied every 3 days for 2 weeks in addition to exercises.
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series.</description>
        </group>
        <group group_id="B2">
          <title>Sham Taping</title>
          <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series.</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Only-exercises group: Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" lower_limit="32.5" upper_limit="53.5"/>
                    <measurement group_id="B2" value="45" lower_limit="41.5" upper_limit="52.25"/>
                    <measurement group_id="B3" value="41.5" lower_limit="34.75" upper_limit="53.25"/>
                    <measurement group_id="B4" value="45" lower_limit="36.5" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Symptoms</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="5.5" upper_limit="8"/>
                    <measurement group_id="B2" value="8" lower_limit="4" upper_limit="10.5"/>
                    <measurement group_id="B3" value="7" lower_limit="5.5" upper_limit="12"/>
                    <measurement group_id="B4" value="8" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nirschl Score</title>
          <description>Nirschl Scoring is a Likert scale ranging from 1 to 7 and classifying LE by the pain phase as a guide to the severity of the problem. Phase 1: Mild pain with exercise, resolves in 24 hours; Phase 2: Pain with exercise, exceeds 48 hours; Phase 3: Pain with exercise, does not alter activity; Phase 4: Pain with exercise, alters activity; Phase 5: Pain with heavy activities of daily living; Phase 6: Pain with light activities of daily living, intermitten pain at rest; Phase 7: Constant pain at rest, disrupts sleep.</description>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="B2" value="4.5" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="B3" value="5" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="B4" value="5" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PRTEE (Patient rated tennis elbow evaluation)</title>
          <description>PRTEE is a 15-item questionnaire designed tomeasure the forearm pain and disability in patients with LET. PRTEE allows patients to rate their levels of elbow pain and disability from 0 to 10 and consists of 2 subscales: 1) Pain subscale [5 items] (0 = no pain, 10 = worst imaginable) 2) Function subscale [Specific activities – 6 items, Usual activities – 4 items] (0 = no difficulty, 10 = unable to do). A total score can be computed on a scale of 100 (0 = no disability).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="43.88" upper_limit="73"/>
                    <measurement group_id="B2" value="53.75" lower_limit="48.62" upper_limit="63"/>
                    <measurement group_id="B3" value="49.25" lower_limit="41" upper_limit="57.5"/>
                    <measurement group_id="B4" value="51" lower_limit="44.25" upper_limit="60.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Rated Tennis Elbow Evaluation (PRTEE)</title>
        <description>PRTEE is a 15-item questionnaire designed to measure the forearm pain and disability in patients with LE. PRTEE allows patients to rate their levels of elbow pain and disability from 0 to 10. Test consists of 2 subscales: 1) Pain subscale [5 items] (0 = no pain, 10 = worst imaginable) 2) Function subscale [Specific activities - 6 items, Usual activities - 4 items] (0 = no difficulty, 10 = unable to do). A total score can be computed on a scale of 100 (0 = no disability).</description>
        <time_frame>0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kinesiotaping</title>
            <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series.</description>
          </group>
          <group group_id="O2">
            <title>Sham Taping</title>
            <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Rated Tennis Elbow Evaluation (PRTEE)</title>
          <description>PRTEE is a 15-item questionnaire designed to measure the forearm pain and disability in patients with LE. PRTEE allows patients to rate their levels of elbow pain and disability from 0 to 10. Test consists of 2 subscales: 1) Pain subscale [5 items] (0 = no pain, 10 = worst imaginable) 2) Function subscale [Specific activities - 6 items, Usual activities - 4 items] (0 = no difficulty, 10 = unable to do). A total score can be computed on a scale of 100 (0 = no disability).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="43.88" upper_limit="73"/>
                    <measurement group_id="O2" value="53.75" lower_limit="48.62" upper_limit="63"/>
                    <measurement group_id="O3" value="49.25" lower_limit="41" upper_limit="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="16.87" upper_limit="39.75"/>
                    <measurement group_id="O2" value="50.25" lower_limit="42" upper_limit="58.37"/>
                    <measurement group_id="O3" value="46.25" lower_limit="37.5" upper_limit="54.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.25" lower_limit="16.37" upper_limit="29.25"/>
                    <measurement group_id="O2" value="47.5" lower_limit="41.37" upper_limit="61.37"/>
                    <measurement group_id="O3" value="44.5" lower_limit="38.87" upper_limit="53.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of baseline values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.643</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of baseline values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.677</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of baseline values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.677</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of baseline values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.326</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.427</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Value</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.545</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.670</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.192</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Disabilities of the Arm, Shoulder and Hand Score (QuickDash)</title>
        <description>The patients will be requested to score from 1 to 5 points any difficulty experienced during different daily activities related to the upper extremity. Test has 1 module of compulsory items and two optional modules: work module (4 items) and sport/performing arts module (4 items). Scores range from 0 to 100, where higher scores indicate more disability.</description>
        <time_frame>0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kinesiotaping</title>
            <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O2">
            <title>Sham Taping</title>
            <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
        </group_list>
        <measure>
          <title>The Disabilities of the Arm, Shoulder and Hand Score (QuickDash)</title>
          <description>The patients will be requested to score from 1 to 5 points any difficulty experienced during different daily activities related to the upper extremity. Test has 1 module of compulsory items and two optional modules: work module (4 items) and sport/performing arts module (4 items). Scores range from 0 to 100, where higher scores indicate more disability.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="41.5" upper_limit="74.43"/>
                    <measurement group_id="O2" value="46.57" lower_limit="38.6" upper_limit="62.49"/>
                    <measurement group_id="O3" value="46.59" lower_limit="33.81" upper_limit="57.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="10.4" upper_limit="59.7"/>
                    <measurement group_id="O2" value="47.72" lower_limit="38.04" upper_limit="53.97"/>
                    <measurement group_id="O3" value="39.77" lower_limit="33.52" upper_limit="49.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks After Treatmentt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.18" lower_limit="4.55" upper_limit="34.1"/>
                    <measurement group_id="O2" value="47.72" lower_limit="34.62" upper_limit="56.81"/>
                    <measurement group_id="O3" value="39.75" lower_limit="31.81" upper_limit="46.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Before Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.633</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.282</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Before Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.677</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Before Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.344</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Before Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.596</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.161</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.257</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.449</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.325</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.323</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.641</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) at Rest</title>
        <description>Pain on lateral epicondyle at rest during the day was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
        <time_frame>0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kinesiotaping</title>
            <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O2">
            <title>Sham Taping</title>
            <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) at Rest</title>
          <description>Pain on lateral epicondyle at rest during the day was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0" upper_limit="3.25"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="3.25"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="3.25"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Immediate effect assessments of tapings are not applicable to control group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="3.25"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.75" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.715</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.907</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.482</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.485</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.129</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.935</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.618</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of immediate effect between groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Immediate effect compared to baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immediate effect compared to baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) at Daily Activity</title>
        <description>Pain on lateral epicondyle during daily activity was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
        <time_frame>0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kinesiotaping</title>
            <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O2">
            <title>Sham Taping</title>
            <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) at Daily Activity</title>
          <description>Pain on lateral epicondyle during daily activity was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5" upper_limit="7.25"/>
                    <measurement group_id="O2" value="7.5" lower_limit="6.75" upper_limit="8"/>
                    <measurement group_id="O3" value="7" lower_limit="5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1.5" upper_limit="6.25"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Immediate effect assessments of tapings are not applicable to control group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="7" lower_limit="5.75" upper_limit="8"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1.75" upper_limit="5.25"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4.75" upper_limit="7.25"/>
                    <measurement group_id="O3" value="5.5" lower_limit="5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.117</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.487</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.102</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.165</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of immediate effect between groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Immediate effect compared to baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immediate effect compared to baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) at Night</title>
        <description>Pain on lateral epicondyle at night was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
        <time_frame>0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kinesiotaping</title>
            <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O2">
            <title>Sham Taping</title>
            <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) at Night</title>
          <description>Pain on lateral epicondyle at night was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="3.5" lower_limit="0" upper_limit="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.25"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="3.25"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.837</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.215</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.699</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.846</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.183</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.719</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.196</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.318</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.483</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Painless Grip Strength</title>
        <description>Grip strength will be measured using a hand held dynamometer (JAMAR, Sammons Preston, Inc., Bolingbrook, IL). Patients will be asked to grip the dynamometer until (s)he feel pain in elbow. Three evaluations will be made with resting periods in between and average scores will be recorded.</description>
        <time_frame>0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kinesiotaping</title>
            <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O2">
            <title>Sham Taping</title>
            <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
        </group_list>
        <measure>
          <title>Painless Grip Strength</title>
          <description>Grip strength will be measured using a hand held dynamometer (JAMAR, Sammons Preston, Inc., Bolingbrook, IL). Patients will be asked to grip the dynamometer until (s)he feel pain in elbow. Three evaluations will be made with resting periods in between and average scores will be recorded.</description>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8" upper_limit="19.75"/>
                    <measurement group_id="O2" value="12" lower_limit="2" upper_limit="25"/>
                    <measurement group_id="O3" value="13" lower_limit="9.5" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="O2" value="13" lower_limit="3.75" upper_limit="27.75"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Immediate effect assessments of tapings are not applicable to control group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="14.75" upper_limit="28.25"/>
                    <measurement group_id="O2" value="13" lower_limit="10" upper_limit="21.25"/>
                    <measurement group_id="O3" value="15" lower_limit="9.5" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="17" upper_limit="28.75"/>
                    <measurement group_id="O2" value="14.5" lower_limit="10" upper_limit="24.5"/>
                    <measurement group_id="O3" value="14.5" lower_limit="9.5" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.897</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.325</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.622</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.909</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.161</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.909</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.255</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.058</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.569</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.614</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of immediate effect between groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.447</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Immediate effect compared to baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immediate effect compared to baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.235</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grip Strength</title>
        <description>Grip strength will be measured using a hand held dynamometer (JAMAR, Sammons Preston, Inc., Bolingbrook, IL). Patients will be asked to grip with maximum strength. Three evaluations will be made with resting periods in between and average scores will be recorded.</description>
        <time_frame>0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kinesiotaping</title>
            <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O2">
            <title>Sham Taping</title>
            <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .</description>
          </group>
        </group_list>
        <measure>
          <title>Grip Strength</title>
          <description>Grip strength will be measured using a hand held dynamometer (JAMAR, Sammons Preston, Inc., Bolingbrook, IL). Patients will be asked to grip with maximum strength. Three evaluations will be made with resting periods in between and average scores will be recorded.</description>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="14.75" upper_limit="27.5"/>
                    <measurement group_id="O2" value="19.5" lower_limit="14.75" upper_limit="30.25"/>
                    <measurement group_id="O3" value="23.5" lower_limit="15" upper_limit="28.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="16.5" upper_limit="29.25"/>
                    <measurement group_id="O2" value="19.5" lower_limit="14.5" upper_limit="32.5"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Immediate effect assessments of tapings are not applicable to control group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="17.5" upper_limit="29.25"/>
                    <measurement group_id="O2" value="20" lower_limit="14.5" upper_limit="27.25"/>
                    <measurement group_id="O3" value="24" lower_limit="19" upper_limit="25.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks After Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="21.5" upper_limit="28.75"/>
                    <measurement group_id="O2" value="21" lower_limit="12" upper_limit="28"/>
                    <measurement group_id="O3" value="24" lower_limit="18.5" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.958</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.597</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.518</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.733</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Baseline Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.404</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.362</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.271</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.519</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of 4 week After Treatment Values</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.569</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p&lt;0.017 is significant</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.973</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.886</p_value>
            <method>Friedman’s two-way analysis of variance</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of immediate effect between groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Immediate effect compared to baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immediate effect compared to baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.734</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Kinesiotaping</title>
          <description>Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
Kinesio taping: Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series.
No adverse effect occured.</description>
        </group>
        <group group_id="E2">
          <title>Sham Taping</title>
          <description>Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
Sham taping: Sham taping will be performed without using any technique
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series.
No adverse effect occured.</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Stretching and strengthening exercises of wrist
Exercise: Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series.
No adverse effect occured.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to Tape</sub_title>
                <description>Contact dermatitis due to tape</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of this study are small sample size and relatively short follow-up time. Also, only patients with symptom duration less than 12 weeks were included so results of the study can not be generalized for chronic lateral epicondylitis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gulseren Derya Akyuz</name_or_title>
      <organization>Marmara University School of Medicine</organization>
      <phone>+90 216 657 06 06 ext 1628</phone>
      <email>girayesra@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

